These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 25727644)
21. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712 [TBL] [Abstract][Full Text] [Related]
22. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030 [TBL] [Abstract][Full Text] [Related]
23. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926 [TBL] [Abstract][Full Text] [Related]
24. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. El Hag MI; Ha J; Farag R; El Hag AM; Michael CW Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760 [TBL] [Abstract][Full Text] [Related]
25. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Bishop JA; Sharma R; Illei PB Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516 [TBL] [Abstract][Full Text] [Related]
26. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983 [TBL] [Abstract][Full Text] [Related]
27. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups. Ni YB; Tsang JY; Chan SK; Tse GM Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335 [TBL] [Abstract][Full Text] [Related]
28. Markers of metastatic carcinoma of breast origin. Gown AM; Fulton RS; Kandalaft PL Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031 [TBL] [Abstract][Full Text] [Related]
29. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases. Boto A; Harigopal M Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697 [TBL] [Abstract][Full Text] [Related]
30. GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. Wang LJ; Greaves WO; Sabo E; Noble L; Tavares R; Ng T; DeLellis RA; Resnick MB Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):505-11. PubMed ID: 19620839 [TBL] [Abstract][Full Text] [Related]
31. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung. Berg KB; Churg A Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203 [TBL] [Abstract][Full Text] [Related]
32. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Miettinen M; Sarlomo-Rikala M Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160 [TBL] [Abstract][Full Text] [Related]
33. A comprehensive analysis of GATA3 expression in carcinomas of various origins with emphasis on lung carcinomas. Bota EC; Koumoundourou D; Ravazoula P; Zolota V; Psachoulia C; Kardari M; Karampitsakos T; Tzouvelekis A; Tzelepi V; Sampsonas F Monaldi Arch Chest Dis; 2023 Aug; 94(2):. PubMed ID: 37667882 [TBL] [Abstract][Full Text] [Related]
34. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764 [TBL] [Abstract][Full Text] [Related]
35. Coexpress of GATA-3 and ER in Anorectal and Head and Neck Squamous Cell Carcinoma Mimicking Metastatic Breast Cancer. Wang Y; Lu S; Amin A; Wang L Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):409-413. PubMed ID: 33264107 [TBL] [Abstract][Full Text] [Related]
36. Evaluating the utility of trefoil factor 1 as a mammary-specific immunostain compared and in conjunction with GATA-3 and mammaglobin in the distinction between carcinoma of breast and lung. Wells JM; Ginter PS; Liu Y; Chen Z; Narula N; Shin SJ Am J Clin Pathol; 2015 Sep; 144(3):444-51. PubMed ID: 26276775 [TBL] [Abstract][Full Text] [Related]
37. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552 [TBL] [Abstract][Full Text] [Related]
38. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. O'Connell FP; Wang HH; Odze RD Arch Pathol Lab Med; 2005 Mar; 129(3):338-47. PubMed ID: 15737028 [TBL] [Abstract][Full Text] [Related]
39. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının. Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727 [TBL] [Abstract][Full Text] [Related]